Tianli Biotech
- Biotech or pharma, therapeutic R&D
TianLi Biotech Pty Ltd (ACN 637 963 556) vision is to transform the wellbeing of patients with chronic respiratory disease. Our mission is to develop innovative, safe, well-tolerated and effective drugs that alleviate suffering of patients with debilitating/fatal respiratory conditions. TianLi Biotech is a Melbourne-based start-up company founded in 2019 in collaboration with The University of Melbourne and Beijing No.1 Biotechnology Group Co., Ltd. The company leveraged the ground-breaking biological discovery that isoforms delta and epsilon of casein kinase 1 (CK1δ/ε) modulate fibrosis and inflammation, into drug development for respiratory diseases for which fibrosis and inflammation are the main features.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}